(109) CONFIRMING ANTI-FIBROTIC EFFECT OF TERFENADINE, EBASTINE, AND SOLIFENACIN IN IN VITRO MODELS OF PEYRONIE’S DISEASE

Abstract Objectives Peyronie’s disease (PD) is characterised by formation of a fibrotic plaque in the tunica albuginea which caused excessive myofibroblast presence and activity. A previous phenotypic screening campaign that tested 1,954 FDA-approved drugs for their ability to inhibit transformation PD-derived fibroblasts revealed 26 hits. Of these, we investigated following hits further; terfenadine (H1-receptor antagonist), ebastine (H3-receptor antagonist) solifenacin (muscarinic receptor antagonist). Methods Tunica PD patients was used isolate primary fibroblasts. The cells were treated with co-incubated transforming growth factor beta 1 (TGF-β1). Full concentration response curves ranging from 0.03 μM 100 constructed quantified measuring α-smooth muscle actin (α-SMA) using In-Cell ELIA (ICE) method. modified ICE quantify total extracellular matrix (ECM) production. results further supported Western blots immunocytochemistry (ICC). Results Terfenadine (IC50 1.7 μM), 4.3 3.5 μM) showed concentration-dependent inhibition α-SMA confirmed blot. ICC stress fibre inhibited all three drugs. ECM formation. blot analysis but not reduced fibronectin expression. Conclusions This first study demonstrate modulating H1-receptor, H3-receptor or muscarinic signalling can affect cells. These have potential repurposing treatment need be vivo studies. Conflicts Interest None